Drugs that contain Efavirenz
1. Sustiva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5811423 | BRISTOL MYERS SQUIBB | Benzoxazinones as inhibitors of HIV reverse transcriptase |
Aug, 2012
(11 years ago) | |
| US5519021 | BRISTOL MYERS SQUIBB | Benzoxazinones as inhibitors of HIV reverse transcriptase |
May, 2013
(10 years ago) | |
|
US5519021 (Pediatric) | BRISTOL MYERS SQUIBB | Benzoxazinones as inhibitors of HIV reverse transcriptase |
Nov, 2013
(10 years ago) | |
| US5663169 | BRISTOL MYERS SQUIBB | Benzoxazinones as inhibitors of HIV reverse transcriptase |
Sep, 2014
(9 years ago) | |
|
US5663169 (Pediatric) | BRISTOL MYERS SQUIBB | Benzoxazinones as inhibitors of HIV reverse transcriptase |
Mar, 2015
(9 years ago) | |
| US6939964 | BRISTOL MYERS SQUIBB | Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
Jan, 2018
(6 years ago) | |
| US6639071 | BRISTOL MYERS SQUIBB | Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
Feb, 2018
(6 years ago) | |
|
US6939964 (Pediatric) | BRISTOL MYERS SQUIBB | Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
Jul, 2018
(5 years ago) | |
|
US6639071 (Pediatric) | BRISTOL MYERS SQUIBB | Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
Aug, 2018
(5 years ago) | |
| US6238695 | BRISTOL MYERS SQUIBB | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
Apr, 2019
(5 years ago) | |
| US6555133 | BRISTOL MYERS SQUIBB | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
Apr, 2019
(5 years ago) | |
|
US6555133 (Pediatric) | BRISTOL MYERS SQUIBB | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
Oct, 2019
(4 years ago) | |
|
US6238695 (Pediatric) | BRISTOL MYERS SQUIBB | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
Oct, 2019
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 02, 2016 |
| Pediatric Exclusivity(PED) | Nov 02, 2016 |
Market Authorisation Date: 17 September, 1998
Treatment: Treatment of hiv infection in combination with one or more additional hiv antiviral agents; Treatment of hiv infection; Treatment of hiv
Dosage: CAPSULE;ORAL; TABLET;ORAL
How can I launch a generic of SUSTIVA before it's drug patent expiration?
More Information on Dosage
SUSTIVA family patents
